Alnylam Pharmaceuticals R&D decreased by 2.0% to $364.87M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 37.6%, from $265.12M to $364.87M. Over 4 years (FY 2021 to FY 2025), R&D shows an upward trend with a 13.6% CAGR.
Analysis
StatementIncome Statement
SectionOperating Expenses
CategoryGrowth
SignalContext dependent
VolatilityStable
First reportedQ4 2013
Last reportedQ4 2025
How to read this metric
High spending signals a commitment to future growth and innovation, though it reduces current period earnings.
Detailed definition
Expenses related to the development of new products, services, and technologies, as well as the improvement of existing...
Peer comparison
Tech leaders often spend a significant percentage of revenue on R&D to prevent disruption by competitors.
Metric ID:
research_and_developmentHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $182.64M | $194.57M | $229.05M | $169.89M | $205.71M | $245.37M | $262.04M | $230.57M | $248.53M | $253.18M | $272.14M | $261.00M | $294.14M | $270.93M | $300.17M | $265.12M | $323.62M | $358.81M | $372.22M | $364.87M |
| QoQ Change | — | +6.5% | +17.7% | -25.8% | +21.1% | +19.3% | +6.8% | -12.0% | +7.8% | +1.9% | +7.5% | -4.1% | +12.7% | -7.9% | +10.8% | -11.7% | +22.1% | +10.9% | +3.7% | -2.0% |
| YoY Change | — | — | — | — | +12.6% | +26.1% | +14.4% | +35.7% | +20.8% | +3.2% | +3.9% | +13.2% | +18.4% | +7.0% | +10.3% | +1.6% | +10.0% | +32.4% | +24.0% | +37.6% |
Range$169.89M – $372.22M
CAGR+15.7%
Avg YoY Growth+17.0%
Median YoY Growth+13.8%
R&D at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's r&d?
- Alnylam Pharmaceuticals (ALNY) reported r&d of $364.87M in Q1 2026.
- How has Alnylam Pharmaceuticals's r&d changed year-over-year?
- Alnylam Pharmaceuticals's r&d increased by 37.6% year-over-year, from $265.12M to $364.87M.
- What is the long-term trend for Alnylam Pharmaceuticals's r&d?
- Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's r&d has grown at a 13.6% compound annual growth rate (CAGR), from $792.16M to $1.32B.
- What does r&d mean?
- The money spent on creating new technology and improving existing products.